In order to expand its portfolio of nutrition products and drug delivery systems, Baxter has agreed to purchase Baxa for US$380 M in cash. Baxa, which reported sales of US$157 M in 2010, develops pharmacy technology that enhances the safety and efficiency of oral and intravenous dose preparation and delivery. The transaction is expected to add to Baxter’s earnings from 2013.